JX-594 Update: Improved Survival for Patients with Advanced Hepatocellular Carcinoma

In this phase II trial of patients with advanced, previously treated hepatocellular carcinoma (HCC),  52% of patients exhibited disease stabilization. The median overall survival was  13.8 mths with 25% of patients survived 32 mths (to date). These data will be presented November 7, 2011 at the 62th Annual Meeting of the American Association for the Study of Liver Diseases.

A Randomized, Controlled Phase 2 Clinical Trial of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Advanced Hepatocellular Carcinoma: Final Data.


Speak Your Mind

*